Iloprost (Iloprost Trometamol)

Iloprost selectively activates the prostacyclin (IP) receptor on vascular smooth‑muscle cells and platelets. This activation raises cyclic AMP levels, causing vasodilation, reducing platelet aggregation, and exerting antiproliferative effects on the vessel wall, which together lower pulmonary arterial pressure and enhance tissue perfusion.

The dosage of Iloprost is individualized and set by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosing regimens may vary, and the prescriber determines the infusion rate, duration, and any titration steps.

The safety of Iloprost in pregnancy and lactation has not been established. It should only be used if the potential benefits justify the possible risks to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Iloprost, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Iloprost belongs to the prostacyclin analog class, offering direct vasodilation via IP‑receptor activation. Compared with endothelin receptor antagonists or phosphodiesterase‑5 inhibitors, Iloprost provides a rapid, infusion‑based effect and also inhibits platelet aggregation, but requires careful monitoring for hypotension and bleeding.

Iloprost solution should be stored at controlled room temperature, below 25 °C. Keep the vial in its original packaging, protect it from light, and avoid exposure to moisture. Do not freeze the product.

Iloprost is administered as an intravenous infusion. The solution is diluted according to the prescribing information and delivered through a controlled infusion pump over a specified period, usually several minutes to hours, under medical supervision.

Serious risks include severe hypotension, pulmonary edema, significant bleeding due to platelet inhibition, and rare cases of thrombocytopenia or acute renal failure. Patients should be monitored closely for these events during and after infusion.

Iloprost is contraindicated in patients with active severe bleeding, uncontrolled hypotension, recent major surgery, or known hypersensitivity to prostacyclin analogs. Caution is also advised for individuals with severe renal impairment or those taking interacting medications such as PDE‑5 inhibitors.